Sentinel lymph node biopsy (SNB)ânavigated neck dissection (ND) could replace elective ND without survival disadvantage and reduce postoperative disability of the neck in patients with early-stage oral cancer, according to results from a Japanese study (Abstract 6007).
During his presentation, Yasuhisa Hasegawa, MD, PhD, of Asahi University Hospital, in Japan, said that another recent study identified a survival benefit with prophylactic ND at the time of primary surgery compared with a âwait and seeâ approach followed by therapeutic ND for nodal relapse in patients with early-stage oral squamous cell carcinoma.
In this trial, the eligibility criteria included histologically confirmed squamous cell carcinoma in the oral cavity that were classified as clinical categories T1 and T2, N0M0 by the Union for International Cancer Control (UICC) TNM classification 7th edition. The clinical depth of invasion of T1 disease was > 4 mm (defined as late T1), and tumours were previously untreated. The primary endpoint was 3-year overall survival (OS), with secondary endpoints including 3-year disease-free survival (DFS), as well as postoperative functional disabilities of the neck and neck complications.
A radioisotope method was used to detect sentinel nodes (SNs), and they were examined with multi-slice frozen section analysis intraoperatively, after hematoxylin and eosin and cytokeratin stain for a final postoperative diagnosis. One-stage or backup neck discussion procedures were used for patients with positive SNs.
Study Results
From November 2011 through January 2016, the researchers identified 275 oral cancers with late T1 or T2N0. There were 137 patients in the ND group and 134 patients in the SNB group who comprised the full analysis set. (Baseline characteristics of the two groups were evenly matched.) In the SNB group, pathologic positive nodal status was 34% (45/134), while in the ND group, the pathologic positive nodal status was 25% (34/137).
Overall, there were 93 patients (34%) who did not undergo neck dissection, 168 patients (62%) who underwent unilateral dissection, and 10 (4%) who underwent bilateral dissection. Postoperatively, 258 patients (95%) did not have any additional therapy (128 patients in the ND group and 130 patients in the SNB group). A total of 10 patients (4%) required radiation/chemoradiation (six patients in the ND group and four patients in the SNB group). The median follow-up was 37 months (interquartile range 36 to 39).
The 3-year OS in SNB group was 88% (95% CI [0.8106, 0.9243]), which was noninferior to the OS in ND group (87%, 95% CI [0.7955, 0.9133]). The 3-year DFS was 79% (95% CI [0.7063, 0.8476]) in SNB group and 81% (95% CI [0.7364, 0.8699]) in the ND group.
âFunctionally, the patients who had SNB had better outcomes at 1 and 3 months,â Dr. Hasegawa said.
Discussant Maie A. St. John, MD, PhD, of the David Geffen School of Medicine, University of California, Los Angeles, said there is level 1 evidence from earlier studies that elective treatment offers a survival advantage, but as metastatic disease occurs in only 20% to 30% of patients, âhow do you avoid overtreating the remaining 70%?â she asked.
âIf no imaging tests are accurate enough to predict the presence of metastatic disease in the neck, SNB should be considered as an alternative to elective ND,â Dr. St. John said. However, there are several reasons why SNB has not âcaught on,â she said, including a concern that it may miss 10% to 15% of occult metastatic disease and that head and neck surgeons are comfortable performing elective NDs.
Posted on
Previous Article
« Endocrine therapy plus ribociclib yields overall survival advantage in HR+/HER2-negative breast cancer Next Article
Letter from the Editors »
« Endocrine therapy plus ribociclib yields overall survival advantage in HR+/HER2-negative breast cancer Next Article
Letter from the Editors »
Table of Contents: ASCO 2019
Featured articles
Endocrine therapy plus ribociclib yields overall survival advantage in HR+/HER2-negative breast cancer
Breast Cancer
Endocrine therapy plus ribociclib yields overall survival advantage in HR+/HER2-negative breast cancer
Biomarker analysis predicts response to adjuvant trastuzumab, pertuzumab in HER2+ breast cancer
Melanoma
Nivolumab-mediated adverse events are independent of efficacy in resected advanced melanoma
Kidney Cancer
Classification of metastatic renal cell carcinoma patients in immunotherapy era and positive responses for sarcomatoid tumours
Sarcoma
Olaratumab trial in soft tissue sarcoma fails to meet overall survival endpoint
Gastrointestinal Cancers
FOLFOXIRI plus bevacizumab an option for patients with mCRC and poor prognosis
KEYNOTE-062: Pembrolizumab combination fails to improve survival in gastric/GEJ cancer
Neoadjuvant chemotherapy as a potential treatment option in colon cancer
Laparascopic surgery; less morbidity, same survival benefits as open surgery in colorectal cancer with liver metastases
Maintenance olaparib improved PFS in patients with BRCA+ pancreatic cancer
Hematologic Malignancies
Daratumumab a promising treatment option for transplant-eligible multiple myeloma
Paediatric Oncology
Entrectinib produces rapid and durable responses in children with refractory CNS and solid tumours
Head and Neck Cancer
Ado-trastuzumab emtansine a potential new treatment option for HER2-amplified advanced salivary gland cancer
Sentinel lymph node biopsy shows promise for early oral cancer
Genitourinary Cancer - Prostate Cancer
Enzalutamide offers survival advantage over other NSAAs in mHSPC
Benefits seen with apalutamide plus ADT in metastatic castration-sensitive prostate cancer
Enfortumab vedotin highly active in previously treated advanced urothelial carcinoma
Multiple Myeloma
Anti-CD38 antibody isatuximab improves treatment response, PFS in R/R multiple myeloma
Lung Cancer
Neoadjuvant nivolumab/ipilimumab shows promise in resectable NSCLC
Overcoming the challenges of immunotherapy in nonâsmall cell lung cancer
Repotrectinib shows encouraging safety, efficacy for patients with ROS1+ NSCLC
Pembrolizumab monotherapy leads to 5-year survival in some patients with NSCLC
Novel RET inhibitor BLU-667 offers promise for RET+ advanced NSCLC
Lurbinectedin shows promise as second-line therapy for SCLC
Early results from TAK-788 in NSCLC with EGFR exon 20 insertions
Developmental Therapeutics - Immunotherapy
IL-6 and C-reactive protein as potential biomarkers for checkpoint inhibition
First-in-human study shows IL1RAP-targeting drug safe in solid tumours
Related Articles
March 21, 2022
Persisting disparities in pancreatic cancer care
Š 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com